# About TB-500 Clinic: An Independent Editorial Research Dossier

> TB-500 Clinic is an independent editorial project that summarizes the peer-reviewed literature on TB-500 and thymosin beta-4. Not a clinic, no clinicians, no products, no medical advice.

An independent editorial dossier on the TB-500 and thymosin beta-4 literature — what the word "clinic" means here, and what it does not.

## What this is

TB-500 Clinic is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 — the synthetic Ac-LKKTETQ fragment of thymosin beta-4 — and on the parent protein itself. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reads like a dossier on purpose. TB-500's defining feature is a single editorial tension — the commercial and anti-doping "TB-500" is the heptapeptide, while nearly all the efficacy data are for the full-length protein — and the whole site is built to keep that distinction in view rather than paper over it. Most writing about this compound collapses the two, citing a full-length thymosin beta-4 result as though it were a TB-500 result. We keep them apart, on every page, because the difference is the single thing a reader most needs and most rarely gets.

The scope is deliberately narrow: this site covers TB-500 and thymosin beta-4, reads the published record, and cites it. It does not cover other peptides except where one is named for contrast. It is a reading of the literature, kept current with the studies as they appear and corrected when we get something wrong.

## What 'clinic' means here

The word "clinic" in this site's name is editorial framing — a position the publisher takes toward the literature, the posture of reading the evidence carefully and clinically — not a claim about services. We do not see patients, write prescriptions, run consultations, or offer treatment. There is no physical location, no phone line, no clinical team.

When this site describes how legally compounded peptide access works under the FDA 503A and 503B framework, it does so as general information about the regulatory landscape, citing FDA. It is not medical or legal advice, and it is not an offer to supply any substance. Anyone making decisions about a specific compound should consult an appropriately licensed professional.

## How we handle the evidence

Every quantitative claim on this site cites a specific study, and each finding is marked for the molecule it was actually measured on — full-length thymosin beta-4 or the TB-500 fragment — and for the species. We surface the gaps as plainly as the findings: where there is no completed human trial of the 7-mer [11], where the dosing was non-monotonic [4], where a registered trial was withdrawn [11], we say so. A research dossier earns trust by what it refuses to overstate, and the honest "NONE" on the front page is as load-bearing as any positive result.

---

A cinematic dark-folio reading of the thymosin beta-4 literature, kept honest about where the Ac-LKKTETQ fragment's human data stop — an editorial dossier, never a clinic and nothing dispensed.